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SULTS: Of the 82 responding geriatric divisions, 15 had
an active ACE unit. Average daily census on ACE units
ranged from 5 to 25, average length of stay was 5.2 days
and the average nurse to patient ratio was 1:6. Commu-
nity dwelling was the most common pre-admission living
setting. Two most common admitting diagnoses were
congestive heart failure and pneumonia. T-test showed
significant difference (.05) between hospitals with ACE
unit and hospitals without, with respect to number of
beds and total revenue. The step-wise logistic regression
indicated that total hospital revenue was the only signifi-
cant factor in determining the presence of an ACE unit.
CONCLUSIONS: Thus, application of the ACE unit
model remains modest given the paucity of information
regarding its long and short-term benefits and cost-effec-
tiveness. Further research in this direction can facilitate
informed policy decisions.
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OBJECTIVE: Given the high cost of pharmaceuticals,
particularly “blockbuster” drugs such as the COX-II in-
hibitors, the issue of value-for-dollar is an increasingly
important one for managed care decision-makers. Due to
the complexity of conducting full economic evaluations,
it is often tempting to try to reduce such analyses to the
most simplistic methods possible—either by assuming
equal effectiveness of two drugs and performing a cost-
minimization analysis, or by using an index of drug cost/
utilization such as DDD (number of defined daily doses
of a drug used in a population), PMPM (per member per
month cost/utilization), PPPM (per patient per month
cost/utilization), ADC (average daily cost of drug ther-
apy), or DACON (daily average consumption of a drug
in a population). If a partial economic evaluation based
on drug cost/utilization is necessary or preferred, deci-
sion-makers should bear in mind the relative strengths
and limitations of these approaches prior to making
policy decisions. The objectives of this paper are: (1) to
describe several indices of drug cost/utilization, (2) to dis-
cuss their strengths and limitations, (3) to provide
illustrations of their use, and (4) to offer suggestions for
appropriate interpretation. METHODS: Using numerical
examples focusing on COX-II inhibitors, several indices
of drug cost/utilization are described and compared, in-
cluding DDD, PMPM, PPPM, ADC, and DACON. Gen-
eral limitations and assumptions of “partial” economic
evaluations based solely upon cost/utilization data are
discussed, including assumptions of equal effectiveness,
compliance, continuation and safety; as well as con-
founding by indication, severity of illness and time on
market. RESULTS: Depending upon the index used, re-
sults (data) on drug cost/utilization for COX-II inhibitors
vary. CONCLUSION: Numerous indices are used to de-
scribe and evaluate drug cost/utilization. Each has its
own strengths and limitations, and must be interpreted in
the appropriate context to best inform pharmaceutical
policy decision-making.
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OBJECTIVES: The study purpose was to describe and
quantify annual costs of pharmaceutical services per cate-
gory (5) and clienteles (5) in a 452 bed mother and child
teaching institution. METHODS: Based on a daily diary
completed by each pharmacist, we calculated costs of
pharmaceutical services in five categories in 1999–2000:
distribution, management, clinical, teaching and research.
Pharmacists were requested to provide a description of
their activities, including the number of new patients/fol-
low-up, verbal and written requests and number/type of
interventions. Costs ratios were calculated. RESULTS:
1999–2000 fiscal year showed 21,330 admissions, 115,961
patient-days and 275,000 outpatient visits. Pharmacists
represented 47% of total worked hours. Pharmacists’ to-
tal hours reported represented 89,6 % of accounting
data. Hours were dedicated to distribution (53%), clini-
cal (29%), management (12%), teaching (5%) and re-
search (1%) services. Pharmacists answered 26 491 ques-
tions while providing 26 065 interventions among 5
clienteles (intensive care, pediatrics, multi-specialties,
mother and child and haematology/oncology). We calcu-
lated a ratio of interventions/worked hours with an aver-
age of 0,61 (min 0,015–max 1,35). An analysis of these
differences will be provided. Pharmacists’ total annual
costs represented $1,453,000.00 CDN including social
benefits. Assuming our pharmacy model optimizes the
number of potential interventions in our setting and that
100 % of pharmacist’s paid time is required to material-
ize them, we calculated an average cost of $54.92 CDN/
intervention (min $24.80 CDN–max $2,233.00 CDN).
Differences were calculated between 1998–1999 and
1999–2000 showing an average of 104% difference (min
68%–max 197%). Differences can be explained by phar-
macist expertise evolution, management decisions and
changes in activity volumes. CONCLUSION: There are
little data available to allow benchmarking in the costs of
pharmaceutical services. Further studies are required to
identify the most useful ratios to monitor such costs as
well as relevant outcomes.
